Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

被引：0

作者：

Amirreza Roostaei Firozabad

Zohreh Akhoundi Meybodi

Seyed Ruhollah Mousavinasab

Adeleh Sahebnasagh

Mohsen Gholinataj Jelodar

Iman Karimzadeh

Solomon Habtemariam

Fatemeh Saghafi

机构：

[1] School of Pharmacy,Pharmaceutical Sciences Research Center, Student Research Committee

[2] Shahid Sadoughi University of Medical Sciences and Health Services,Infectious disease research center

[3] Shahid Sadoughi hospital,Resident of Clinical Pharmacy, Department of Clinical Pharmacy

[4] Shahid Sadoughi University of Medical Sciences,Clinical Research Center, Department of Internal Medicine, School of Medicine

[5] School of Pharmacy,Department of Internal Medicine

[6] Shiraz University of Medical Sciences,Department of Clinical Pharmacy

[7] North Khorasan University of Medical Sciences,Pharmacognosy Research Laboratories and Herbal Analysis Services UK

[8] School of Medicine,Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center

[9] Shahid Sadoughi University of Medical Sciences,undefined

[10] School of Pharmacy,undefined

[11] Shiraz University of Medical Sciences,undefined

[12] University of Greenwich,undefined

[13] Shahid Sadoughi University of Medical Sciences,undefined

来源：

BMC Infectious Diseases | / 21卷

关键词：

Levamisole; Hydroxychloroquine; COVID-19; SARS-CoV2; Clinical status;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 183 条

[1] Phelan AL(2020)The novel coronavirus originating in Wuhan, China: challenges for global health governance JAMA. 323 709-710
[2] Katz R(2020)SARS-CoV-2 is an appropriate name for the new coronavirus Lancet 395 949-950
[3] Gostin LO(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China JAMA 323 1061-1069
[4] Wu Y(2020)SARS-CoV-2 and coronavirus disease 2019: what we know so far Pathogens. 9 231-1928
[5] Ho W(2014)Coronavirus cell entry occurs through the endo−/lysosomal pathway in a proteolysis-dependent manner PLoS Pathog 10 e1004502-879
[6] Huang Y(1991)Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein J Virol 65 1916-635
[7] Jin D-Y(2017)Induction of atypical autophagy by porcine hemagglutinating encephalomyelitis virus contributes to viral replication Front Cell Infect Microbiol 7 56-506
[8] Li S(2005)A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury Nat Med 11 875-68
[9] Liu S-L(2020)A perspective on erythropoietin as a potential adjuvant therapy for acute lung injury/acute respiratory distress syndrome in patients with covid-19 Arch Med Res 51 631-254
[10] Liu X(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-721